PCI expands high potent tabletting at Wales facility
Pharmaceutical outsourcing provider PCI Pharma Services (PCI) has announced it is expanding its manufacturing centre in Wales as part of an investment drive.
The company will double its highly potent tabletting capacity at its Tredegar centre to increase general throughput to support recent and future product launches.
The expansion comes as part of the company’s recent investment drive, made in direct response to customer needs and market growth.
PCI’s Richard Yarwood, senior vice president, said: “We are delighted to announce these most recent investments as part of both our business continuity and growth strategies. This additional capacity will provide greater security to our customers, supporting important clinical programs and new product or market launches.”
PCI opened its Tredegar site in 2013 and has since enhanced the facility through additional investments to delivery cost and time efficiencies for customers. For instance, PCI has invested in technologies to support the processing of highly potent liquids and semi-solids to complete its offering for multiple dosage forms.
Most recently PCI extended the capacity of its analytical laboratory in support of growth in the potent market. The laboratory project increased analytical capacity to support development and commercial raw material, in-process and finished product testing. The layout design incorporated lean philosophies and optimised safety with the installation of specific, high potent drug containment enclosures.
Commenting on these investments, Yarwood said: “We have developed the PCI Tredegar site in direct response to growing customer demand for the development and commercial supply of potent drug products. We are proud to be a trusted partner to more than half of the top 20 pharmaceutical companies globally and our investments have been carefully considered to ensure we keep pace with customer needs, today and in the future.”
He continued: “PCI has built significant experience in the effective processing of these often challenging highly potent molecules. Our customers value us for our ongoing investment in leading-edge technology, combined with the commitment of our highly skilled scientists and trained.”